Mesenbio is a preclinical-stage biotech company leveraging extracellular vesicles (EVs) derived from clonally selected, immortalized mesenchymal stem cell (MSC) lines to develop innovative therapies for arthritic diseases. Our approach is designed to harness the regenerative and anti-inflammatory properties of EVs, aiming to transform treatment outcomes for patients. We are strategically focused on advancing our preclinical research and de-risking our technology platform to pave the way for clinical trials in the future.